The Journey of Sertraline

Sertraline is well absorbed after oral administration with absolute
bioavailability of approximately 44% due to hepatic first-pass metabolism. Peak plasma concentrations
are achieved in 4-6 hours. A notable feature is that food significantly increases both peak
concentration and overall AUC: taking sertraline with food increases AUC by approximately 30% and
nearly doubles Cmax compared to the fasted state — clinically used to improve tolerability and
consistency by recommending morning administration with a meal. The oral solution and tablet
formulations have comparable bioavailability. Sertraline undergoes extensive first-pass metabolism
in the gut wall (CYP3A4) and liver (CYP2C19, CYP2C9, CYP2D6), which limits systemic availability
but is not saturable within the therapeutic dose range (25-200 mg/day).

Sertraline is extensively distributed throughout body tissues
with a volume of distribution of approximately 20 L/kg, indicating substantial tissue penetration
including the CNS. Plasma protein binding is high at approximately 98%, primarily to albumin and
alpha-1-acid glycoprotein. High protein binding contributes to its large apparent volume of
distribution despite plasma concentrations in the nanomolar range. The drug crosses the blood-brain
barrier readily due to its lipophilicity (logP ~5.3). Breast milk concentrations are detectable,
though infant plasma levels are generally low and considered compatible with breastfeeding by most
guidelines. Sertraline achieves steady-state plasma concentrations after approximately 7 days of
once-daily dosing.

Sertraline is a selective serotonin reuptake inhibitor (SSRI) that
binds with high affinity and selectivity to the serotonin transporter (SERT, SLC6A4) — the
monoamine transporter that terminates serotonergic neurotransmission by reuptaking 5-hydroxytryptamine
(serotonin, 5-HT) from the synapse back into the presynaptic neuron. Sertraline occupies the central
substrate-binding site of SERT (the S1 site) in an occluded conformation, preventing the
conformational changes required for 5-HT translocation. Binding is competitive with 5-HT. The
immediate consequence of SERT blockade is increased synaptic serotonin — but therapeutic antidepressant
effects require 2-6 weeks, explained by the monoamine hypothesis extension: chronic SERT blockade
desensitizes inhibitory 5-HT1A somatodendritic autoreceptors, ultimately increasing serotonergic
firing and synaptic 5-HT tone. Downstream effects include neurogenesis in the hippocampus, BDNF
upregulation, and HPA axis normalization.

Sertraline is extensively metabolized in the liver via multiple
CYP isoforms. The primary pathway is N-demethylation to desmethylsertraline (norsertraline) by
CYP2C19, CYP2C9, CYP2D6, and CYP3A4. Desmethylsertraline has approximately 10-fold lower
potency at SERT than the parent drug and is not considered clinically active at systemic concentrations.
Desmethylsertraline is further metabolized by oxidative deamination and ketone reduction. Sertraline
is a moderate inhibitor of CYP2D6, which can elevate levels of co-administered drugs metabolized by
this enzyme (tricyclic antidepressants, some antipsychotics, metoprolol, codeine activation pathway).
CYP2C19 poor metabolizers have approximately 40-50% higher sertraline exposure. Food effect on
sertraline metabolism is primarily mediated through changes in hepatic blood flow and first-pass
extraction rate.

Sertraline and its metabolites are excreted in approximately equal
proportions in urine and feces. Less than 0.2% of the dose is excreted as unchanged sertraline in
urine. Elimination half-life is approximately 26 hours (range 22-36 hours), supporting once-daily
dosing. Desmethylsertraline has a longer half-life of 62-104 hours. Steady-state concentrations of
both parent and metabolite are achieved within approximately one week. No dose adjustment is required
for renal impairment (renal excretion is minimal). For severe hepatic impairment, dose reduction
and caution are advised due to reduced first-pass and elimination. Sertraline is not significantly
removed by hemodialysis.

Sertraline is FDA-approved for major depressive disorder, obsessive-
compulsive disorder, panic disorder, PTSD, social anxiety disorder, and premenstrual dysphoric
disorder — the broadest indication range of any SSRI. Common adverse effects include GI symptoms
(nausea, diarrhea — improved by taking with food), insomnia, sexual dysfunction (delayed ejaculation,
anorgasmia, reduced libido), and activation syndrome in early treatment. Serotonin syndrome risk
is elevated when combined with MAO inhibitors, triptans, linezolid, or tramadol. Abrupt discontinuation
causes discontinuation syndrome (dizziness, electric shock sensations, irritability) managed by gradual
tapering. The FDA black box warning for increased suicidality in children and adolescents applies to
all antidepressants.